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Abstract
Background:  Single-dose nevirapine (SDNVP) for the prevention of mother-to-child HIV
transmission (PMTCT) results in the selection of resistance mutants among HIV-infected mothers.
The effects of these mutations on the efficacy of SDNVP use in a subsequent pregnancy are not
well understood.
Methods: We compared risks of perinatal HIV transmission between multiparous women who
had previously received a dose of SDNVP (exposed) and those that had not (unexposed) and who
were given SDNVP for the index pregnancy within a PMTCT clinical study. We also compared
transmission risks among exposed and unexposed women who had two consecutive pregnancies
within the trial. Logistic regression modeling was used to adjust for possible confounders.
Results:  Transmission risks did not differ between 59 SDNVP-exposed and 782 unexposed
women in unadjusted analysis or after adjustment for viral load and disease stage (adjusted odds
ratio 0.6, 95% confidence interval [CI] 0.2 to 2.0). Among 43 women who had two consecutive
pregnancies during the study, transmission risks were 7% (95% CI 1% to 19%) at both the first
(unexposed) and second (exposed) delivery. The results were unchanged, if infant death was
included as an outcome.
Conclusion: These data suggest that the efficacy of SDNVP may not be diminished when reused
in subsequent pregnancies.
Background
Single-dose nevirapine (SDNVP) given at the onset of
labor to the mother and within 72 hours of birth to the
infant is a safe, efficacious, simple and cost-effective inter-
vention for the prevention of mother-to-child HIV trans-
mission (PMTCT) [1]. It has been widely implemented in
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resource-constrained countries, where more complex and
potent regimens are not available [2].
A drawback of this regimen is the selection of resistance
mutations in a large proportion of exposed women and
their infected infants [2]. These mutations may reduce
virologic susceptibility to treatment with non-nucleoside
reverse transcriptase inhibitor-based regimens if initiated
soon after delivery [3,4]. The mutations may also remain
detectable in a small proportion of women at above pre-
exposure levels as late as 1 year post-partum [5-7], raising
concerns that use of this regimen for PMTCT in subse-
quent pregnancies compromises the efficacy of the inter-
vention.
Studies from South Africa/Cote d'Ivoire [8] and Uganda
[9] have found no decrease in SDNVP efficacy during sub-
sequent pregnancies. However, these studies included few
subtype C infected women, who may have a higher fre-
quency of resistant strains after exposure to SDNVP [10].
The predominant subtype in circulation in Zambia is C.
We compared the transmission risk associated with use of
SDNVP in repeat pregnancies among women enrolled in
a clinical PMTCT trial in Zambia [11]. Among study par-
ticipants with at least one previous live birth (multipa-
rous) who were given SDNVP for the study, we compared
the perinatal HIV transmission risk between women who
reported previous SDNVP use and those who did not. In a
second analysis, we compared transmission risks between
the first (unexposed) and second (SDNVP-exposed) deliv-
ery of a subset of women who had two consecutive preg-
nancies within the study.
Methods
Study procedures
Women were enrolled in the Zambia Exclusive Breastfeed-
ing Study at two antenatal clinics in Lusaka, Zambia,
between April 2001 and May 2004 [11,12]. All women
were given a 200 mg tablet of nevirapine to be taken at the
onset of labor. At delivery, women were asked if and when
they had consumed the nevirapine tablet. If more than 48
hours had passed or they had not taken it, they were given
a second dose. The newborn received 0.6 ml nevirapine
suspension as soon as possible after the delivery. All
women were counseled to exclusively breastfeed until at
least four months. As part of prenatal care, all women
were offered multivitamins, presumptive malaria prophy-
laxis and starting in November 2003 cotrimoxazole
prophylaxis if enrolment CD4 cell counts were below 200
cells per μl [13]. Antiretroviral treatment only became
available in late 2004, towards the end of the study.
Maternal blood samples were collected at enrolment,
CD4 counts (BD Immunocytometry Systems, San Jose,
CA) and plasma viral load (Roche Amplicor® version 1.5,
Branchburg, NJ) were determined. Women were asked
about HIV-related clinical conditions and WHO clinical
stage was assigned based on these self-reports. To account
for pregnancy-related weight gain, any weight loss was cat-
egorized as severe. Weight and height was measured and
Body Mass Index (BMI) calculated as kg per square meter.
Infant dried blood spots were collected at delivery, one
week, one month, at least monthly until 6 months of age
and then every 3 months until the end of the follow-up at
24 months and tested for HIV DNA by polymerase chain
reaction (PCR) as described previously [11].
The study was approved by the Institutional Review
Boards of the investigators' institutions and all partici-
pants provided written informed consent.
Statistics
HIV transmission events were included in the analysis if
they occurred within 42 days post-partum to allow for var-
iation in the time of the 1 month HIV test. Timing of HIV
transmission was categorized by the PCR test results as
intrauterine (infant PCR positive within 3 days of deliv-
ery), or intrapartum/early breastfeeding (between 4 and
42 days postpartum). For multiple births, the first live-
born infant was included in the analysis. Birth weight of
infants born at home was only included in the analysis if
the infants were presented at the clinic within 3 days after
delivery.
We used the chi-square test, or if the expected cell size was
below 5 we used Fisher's Exact Test, to compare categori-
cal variables, Cochran-Armitage Trend Test for ordered
categorical variables, the T-test to compare normally-dis-
tributed continuous variables and the Wilcoxon Rank
Sum Test to compare non-normally-distributed continu-
ous variables. Logistic regression modeling was conducted
to adjust for possible confounding. Consecutive deliveries
of women during the study were compared using paired T-
tests for normally distributed variables, the Wilcoxon
Signed Rank Test for non-normally distributed continu-
ous paired variables, and the McNemar Test for categorical
variables. Asymptotic p-values were calculated for McNe-
mar Test, unless the expected cell counts were less than 5
in which case, exact values were calculated. Exact bino-
mial confidence intervals were calculated for the transmis-
sion risks among women with two deliveries.
All statistical analyses were performed using SAS software
(Version 9.1, Cary, NC).
Results
Study population
Figure 1 illustrates the selection of the study cohort. We
excluded primiparous women, women who did not know
if they had been exposed to SDNVP, women with a self-BMC Infectious Diseases 2008, 8:172 http://www.biomedcentral.com/1471-2334/8/172
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Repeated SDNVP exposure within the Zambia Exclusive Breastfeeding Study and selection of the study cohort Figure 1
Repeated SDNVP exposure within the Zambia Exclusive Breastfeeding Study and selection of the study 
cohort.BMC Infectious Diseases 2008, 8:172 http://www.biomedcentral.com/1471-2334/8/172
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reported exposure that contradicted the study documenta-
tion, as well as women on antiretroviral treatment during
pregnancy. To assure statistical independence of the
groups, we further limited the study population to one
delivery (i.e. the second) per woman, resulting in the
inclusion of 62 deliveries of SDNVP-exposed and 853 of
unexposed women. Similar frequencies of infants died (1
(2%) versus 18 (2%), p = 1.0) or were lost to follow-up (2
(3%) versus 53 (6%), p = 0.58) before their HIV-status
could be determined, resulting in a final study cohort of
59 exposed and 782 unexposed women.
Of the 59 exposed women, 45 (76%) had received nevi-
rapine at a preceding delivery within our study, nine
(15%) reported participation in an earlier study at the
same site and for 5 (8%) the source of exposure was
unknown.
Unexposed women had a higher viral load and more
advanced disease stage (≥ stage III) at enrolment than
SDNVP-exposed women. They also had fewer previous
live births, lower BMI, and tended to have infants of lower
birth weight. CD4 counts were not significantly different
(Table 1).
HIV transmission risks between SDNVP-exposed and 
unexposed
The risk for perinatal HIV transmission and the risk for
combined HIV transmission and infant death ≤ 42 days
post-partum did not significantly differ by maternal expo-
sure to nevirapine and was slightly lower in the exposed
Table 1: Characteristics HIV-infected multiparous mothers and their infants by previous exposure to single-dose nevirapine (SDNVP).
Mother previously nevirapine exposed Mother previously nevirapine un-exposed p-value
Na 59 782
Socio-demographic variables
Maternal age [mean ± SD] 27.3 ± 5.1 26.9 ± 4.9 0.59
Number of previous live births [median 
(IQR)]
3 (2, 4) 2 (1, 3) 0.001
HIV-related factors at enrolment
HIV viral load [copies per ml ]
Median (IQR) 20,501 (7,001; 60,617) 39,401 (9,728; 130,058) 0.04
< 10 000 [N (%)] 17 (29) 202 (26)
10 000–99 999 [N (%)] 31 (53) 346 (44)
≥ 100 000 [N (%)] 10 (17) 232 (30) 0.11 (trend)
CD4 cells [counts per μl]
Median (IQR) 335 (222, 453) 316 (190, 468) 0.86
< 200 14 (24) 205 (26)
200–349 19 (33) 238 (30)
≥ 350 25 (43) 338 (43) 0.86 (trend)
N (%) WHO clinical stage III 11 (19) 337 (43) 0.0002
BMI at 1 month post partum [mean ± SD] 22.7 ± 3.2 21.7 ± 3.4 0.03
Hemoglobin [g/dl] [mean ± SD] 10.9 ± 1.5 10.6 ± 1.5 0.12
Positive rapid plasma regain test for syphilis 
[N (%)]
6 (11) 135 (18) 0.15
Obstetric and infant variables
Caesarean sections [N (%)] 1 (2) 14 (2) 1.0
Low birth weight [N (%) < 2500 g] 2 (4) 83 (11) 0.07
Birth weight [mean ± SD] 3077 ± 439 3015 ± 496 0.36
Preterm delivery [N (%) ≤ 34 weeks of 
gestation]
11 (19) 178 (23) 0.50
Sex [N (%) male] 26 (44) 407 (52) 0.23
Nevirapine prophylaxis at current delivery
Maternal dose taken [N (%)] 58 (98) 745 (95) 0.51
Infant dose taken [N (%)] 57 (98) 733 (95) 0.35
HIV transmission and infant mortalityb
Infants HIV positive ≤ day 42 [N (%)] 3 (5) 94 (12) 0.11
Infants HIV positive or died ≤ day 42 [N 
(%)]c
4 (7) 127 (16) 0.06
a) numbers may differ from the total due to missing data
b) Loss to follow-up at 42 days (as defined as HIV-uninfected, did not die ≤ 42 days, but was last tested before the one month visit) was not 
significantly different between both groups (1 (2%) versus 63 (8%), p = 0.08).
c) The study size for the combined analysis of infant mortality and HIV transmission was slightly larger as it includes 1 infant in the exposed and 18 
in the unexposed group who died before the HIV status was established.BMC Infectious Diseases 2008, 8:172 http://www.biomedcentral.com/1471-2334/8/172
Page 5 of 7
(page number not for citation purposes)
group (exposed: 3 (5%) versus unexposed: 94 (12%), p =
0.11) (Table 1). The risks were also similar if further strat-
ified by the probable timing of HIV transmission: intrau-
terine – 1 (2%) versus 49 (6%), p = 0.25 – and
intrapartum/early breastfeeding – 2 (3%) versus 45 (6%),
p = 0.57 in exposed versus unexposed deliveries respec-
tively.
There continued to be no association between maternal
SDNVP exposure status and transmission after adjusting
for confounding by logistic regression. In these models,
the adjusted odds ratio (AOR) for HIV transmission ≤ 42
days post-partum among exposed relative to unexposed
was 0.6 (95% CI: 0.2 to 2.0) after adjusting for maternal
viral load (AOR 3.0, 95% CI 2.1 to 4.2 per log10 increase)
and maternal clinical stage (AOR: 1.8, 95% CI 1.1 to 2.8).
None of the other factors listed in Table 1 was independ-
ently associated with the transmission risk if added to the
above model, or substantially changed the estimate of the
nevirapine exposure effect. The results were similar, if the
combined risk for HIV transmission and infant death was
chosen as the outcome.
Women with two deliveries within the study
Of the 45 women who had two live births during the
study, 2 reported a previous exposure to SDNVP at their
first enrolment. One of them transmitted HIV to their
infant at the second exposed delivery (the first within the
study), however neither of them transmitted at the third
exposed delivery. We next compared transmission risks
between the remaining 43 women with an unexposed and
a subsequently exposed delivery.
The median time between the two deliveries was 22
months (range 12 to 42 months, IQR: 17 to 31 months),
during which the median CD4 cell count declined by 96
cells per μl. There was no significant difference in the viral
load between pregnancies (Table 2) with only 4 women
decreasing by more than 0.7 log10 copies per ml and 4
increasing by more than 0.7 log10 copies per ml. In most
of the other characteristics the women were comparable at
their first and second pregnancy (Table 2).
The risk for HIV transmission did not differ between the
SDNVP-naive and exposed pregnancies (3 (7%), 95% CI:
1% to 19% in both groups, p = 1.0) with similar numbers
of intrauterine (0 versus 1) and intrapartum/early breast-
feeding transmissions (3 versus 2) (Table 2). These six
transmissions occurred to 5 different women, as one
mother transmitted HIV in both deliveries (intrapartum/
early breastfeeding at first and intrauterine at the second).
Table 2: HIV transmission among 43 HIV-infected women who had two deliveries within the study.
Mother previously nevirapine un-exposed 
(first delivery)
Mother previously nevirapine exposed 
(second delivery)
p-value
Socio-demographic variables
Maternal age [mean ± SD] 25.3 ± 4.7 27.3 ± 4.9 < 0.0001
Primipara [N (%)] 5 (12) 0 (0) /
HIV-related factors at enrolment
HIV viral load [median copies per ml 
(IQR)]
30,412 (6,864; 80,557) 18,918 (7,162; 78,152) 0.34
CD4 cells per μl [median (IQR)] 430 (303, 595) 334 (188, 460) < 0.0001
Disease stage III [N (%)] 14 (33) 9 (21) 0.30
BMI at 1 month post partum [mean ± 
SD]
21.4 ± 2.8 22.4 ± 3.1 0.007
Hemoglobin [g/dl] [mean ± SD] 10.7 ± 1.5 11.0 ± 1.4 0.24
Positive rapid plasma regain test for 
syphilis [N (%)]
9 (22) 5 (12) 0.22
Obstetric and infant variables
Caesarean sections [N (%)] 2 (5) 0 (0) /
Low birth weight [N (%) < 2500 g] 5 (12) 2 (5) 0.45
Birth weight [mean ± SD] 3029 ± 536 3042 ± 469 0.82
Preterm delivery [N (%) ≤ 34 weeks of 
gestation]
5 (12) 8 (19) 0.75
Sex [N (%) male] 23 (53) 16 (37) 0.14
Nevirapine prophylaxis at current delivery
Maternal dose taken [N (%)] 43 (100) 43 (100) /
Infant dose taken [N (%)] 40 (93) 41 (98) 1.0
HIV transmission and infant mortality
Infants HIV positive ≤ day 42 [N (%)] 3 (7) 3 (7) 1.0
Infants HIV positive or died ≤ day 42 [N 
(%)]
4 (9) 3 (7) 1.0
Numbers may differ from the total due to missing dataBMC Infectious Diseases 2008, 8:172 http://www.biomedcentral.com/1471-2334/8/172
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Discussion
In this well-defined cohort of HIV-infected women in
Lusaka, Zambia, the reuse of SDNVP for PMTCT at a sub-
sequent pregnancy did not reduce the efficacy of the inter-
vention. Women who reported use of SDNVP in a
previous pregnancy had transmission rates that were sim-
ilar to multiparous women who were drug naïve. Moreo-
ver, women who used SDNVP for two pregnancies during
the study did not experience increased transmission rates
in the second pregnancy, despite having demonstrable
progression in their HIV disease as indicated by a decline
in CD4 cell counts of nearly 100 cells/uL. In conjunction
with the previous published studies from South Africa/
Cote d'Ivoire [8] and Uganda [9], these data indicate that
reuse of SDNVP may not be associated with a loss of effi-
cacy.
Our observations suggest that persistent small pools of
resistant mutants do not affect the efficacy of subsequent
courses of SDNVP for later pregnancies. Resistant viral
variants may be created and can remain detectable for as
long as one year post-exposure [5-7]. But because they do
not seem to interfere with the ability of nevirapine to pre-
vent transmission in subsequent deliveries, we assume
that they represent a small and insignificant fraction of
maternal virus. Our findings are therefore concordant
with a model in which SDNVP efficacy relies on the inhi-
bition of the majority of circulating strains. However, such
a mechanism is in contrast to treatment efficacy, which is
compromised by resistance mutations if started within 6–
18 months after SDNVP exposure [3,4,14].
The main limitation of this study is its small size. Power
calculations indicate that we had sufficient power (> 80%
with two-tailed alpha of 5%) to detect a difference in
transmission rates of 14% for the comparison between
women (Table 1). While these data therefore cannot be
seen as definite evidence per se, the cumulative evidence
suggests that SDNVP will remain efficacious independent
of subtype and geographic region.
The mean time between deliveries in our study of 22
months is comparable to the difference observed in the
two preceding studies [8,9]. Our ability to assess the effi-
cacy of second dosing of SDNVP during a subsequent but
more closely spaced pregnancy is limited. However, detec-
tion and fading of nevirapine resistance is similar regard-
less of whether nevirapine exposure is repeated or for the
first time [15,16].
Conclusion
SDNVP does not appear to lose it's efficacy for preventing
mother-to-child transmission when repeat dosing occurs
during subsequent pregnancies in HIV-infected women in
Zambia. SDNVP is likely to remain an effective prevention
method for Zambia and other resource-limited settings
where more complex and efficacious regimens [17] have
not yet become available.
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